Avidity Based Binding Assay

Description: The human IDO1 Cell-Based Assay Kit is designed to monitor the activity of exogenously expressed human IDO1 in cultured cells.

Description: The Cereblon Binding Assay Kit (FP) is designed for testing and profiling of Cereblon (CRBN) inhibitors using Fluorescence Polarization. The assay is a competitive binding assay, based on the binding of fluorescently-labeled Thalidomide, a CRBN binder, to purified recombinant CRBN._x000D_ CRBN is the substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins. CRBN is a direct protein target for the immunomodulatory and antiproliferative activities of thalidomide analogues such as lenalidomide and pomalidomide._x000D_ The Cereblon Binding Assay Kit (FP) comes in a convenient 96-well format, with enough purified CRBN, Cy5-labeled Thalidomide, and assay buffer for 100 enzyme reactions. In addition, the kit includes the CRBN inhibitor Pomalidomide for use as an inhibitor control._x000D_
The key to the CRBN Assay Kit is the fluorescently-labeled Thalidomide. Using this kit, only one simple step on a microtiter plate is required for CRBN reactions. The Cy5-labeled Thalidomide is incubated with a sample containing CRBN to produce a change in fluorescent polarization that can be measured using a fluorescence reader.

Description: The Von Hippel–Lindau tumor suppressor (VHL) Binding Assay Kit is a homogeneous assay which measures the binding of VHL to the high-affinity VHL fluorescent probe (BDY FL VH032) using Fluorescence Polarization (FP) . In addition, the kit includes the VHL inhibitor VH298 for use as an inhibitor control. This assay takes advantage of the fluorescent substrate BDY FL VH032. Using this kit, only one step on a 96-well plate is required. The BDY FL VH032 is incubated with the VHL complex in the presence of a compound of interest to produce a change in fluorescent polarization. The FP signal is measured using a fluorescent microplate readercapable of measuring fluorescence polarization.Need us to run inhibitor screens or profile your compounds against VHL Binding? Check out ourUbiquitination Screening Services.

Description: The Von Hippel–Lindau tumor suppressor (VHL) Binding Assay Kit is a homogeneous assay which measures the binding of VHL to the high-affinity VHL fluorescent probe (BDY FL VH032) using Fluorescence Polarization (FP) . In addition, the kit includes the VHL inhibitor VH298 for use as an inhibitor control. This assay takes advantage of the fluorescent substrate BDY FL VH032. Using this kit, only one step on a 96-well plate is required. The BDY FL VH032 is incubated with the VHL complex in the presence of a compound of interest to produce a change in fluorescent polarization. The FP signal is measured using a fluorescent microplate readercapable of measuring fluorescence polarization.Need us to run inhibitor screens or profile your compounds against VHL Binding? Check out ourUbiquitination Screening Services.

Description: The Cereblon Binding Assay Kit (FP) is designed for testing and profiling of Cereblon (CRBN) inhibitors using Fluorescence Polarization. The assay is a competitive binding assay, based on the binding of fluorescently-labeled Thalidomide, a CRBN binder, to purified recombinant CRBN._x000D_ CRBN is the substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins. CRBN is a direct protein target for the immunomodulatory and antiproliferative activities of thalidomide analogues such as lenalidomide and pomalidomide._x000D_ The Cereblon Binding Assay Kit (FP) comes in a convenient 96-well format, with enough purified CRBN, Cy5-labeled Thalidomide, and assay buffer for 100 enzyme reactions. In addition, the kit includes the CRBN inhibitor Pomalidomide for use as an inhibitor control._x000D_
The key to the CRBN Assay Kit is the fluorescently-labeled Thalidomide. Using this kit, only one simple step on a microtiter plate is required for CRBN reactions. The Cy5-labeled Thalidomide is incubated with a sample containing CRBN to produce a change in fluorescent polarization that can be measured using a fluorescence reader.

Description: The EZH2-EED Binding Assay Kit is designed to measure the inhibition of the_x000D_protein-protein interaction between EZH2 and EED. The key to this kit is the specific binding of EZH2 to EED. With this kit, only two_x000D_simple steps on a microtiter plate are required. First, incubate a sample containing EZH2, EED_x000D_and an inhibitor of choice. Next, incubate with a mixture of acceptor and donor beads, followed_x000D_by reading the Alpha-counts.

Description: The PCSK9 (His) -LDLR Binding Assay Kit is an ELISA-type 96-well format assay designed for screening and profiling purposes. Moreover, two pre-formulated assay buffers are supplied to validate PCSK9-LDLR binding affinity in either neutral or acidic binding conditions. The assay takes advantage of the high sensitivity of detection of His-tag PCSK9 by Anti-His HRP-antibody. First, the LDLR ectodomain is coated on a 96-well plate. Next, PCSK9 is incubated with LDLR on the plate. Finally, the plate is treated with Anti-His HRP-antibody followed by addition of an HRP substrate to produce chemiluminescence, measured using a chemiluminescence reader.Figure 1: Illustration of the ELISA-based PCSK9 (His) -LDLR Binding Assay Kit.Need us to run inhibitor screens or profile your compounds against PCSK9 (His) -LDLR? Check out ourPCSK9 Screening Services.

Description: The PCSK9 (His) -LDLR Binding Assay Kit is an ELISA-type 96-well format assay designed for screening and profiling purposes. Moreover, two pre-formulated assay buffers are supplied to validate PCSK9-LDLR binding affinity in either neutral or acidic binding conditions. The assay takes advantage of the high sensitivity of detection of His-tag PCSK9 by Anti-His HRP-antibody. First, the LDLR ectodomain is coated on a 96-well plate. Next, PCSK9 is incubated with LDLR on the plate. Finally, the plate is treated with Anti-His HRP-antibody followed by addition of an HRP substrate to produce chemiluminescence, measured using a chemiluminescence reader.Figure 1: Illustration of the ELISA-based PCSK9 (His) -LDLR Binding Assay Kit.Need us to run inhibitor screens or profile your compounds against PCSK9 (His) -LDLR? Check out ourPCSK9 Screening Services.